Monte Rosa Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
GLUE$10.50-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated statements of cash flows
Cons olidated statements of cash flows
| Year ended December 31, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| Cash flows from operating activities: | ||
| Net loss | $(38,626) | $(72,700) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 18,865 | 18,126 |
| Depreciation | 8,356 | 8,121 |
| Net accretion of discounts/premiums on marketable securities | (2,145) | (2,948) |
| Gain on disposal of property and equipment | (59) | — |
| Changes in operating assets and liabilities | ||
| Collaboration receivable | (7,000) | — |
| Other receivables | (4,427) | 332 |
| Prepaid expenses and other assets | 604 | (1,588) |
| Accounts payable | (13,708) | 6,252 |
| Accrued expenses and other current liabilities | 7,852 | 4,184 |
| Defined benefit plan liability | 1,045 | 187 |
| Right-of-use assets and operating lease liabilities | (1,079) | (1,348) |
| Deferred revenue | 7,524 | 83,378 |
| Net cash (used in) provided by operating activities | $(22,798) | $41,996 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (4,700) | (3,988) |
| Purchases of marketable securities | (376,675) | (230,361) |
| Proceeds from maturities of marketable securities | 279,542 | 189,897 |
| Net cash used in investing activities | $(101,833) | $(44,452) |
| Cash flows from financing activities: | ||
| Proceeds from sale of common stock pursuant to the at-the-market sales agreement, net of underwriter's discount | 24,250 | 944 |
| Proceeds from underwritten public offering, net of underwriter's discount of $3,000 | — | 47,001 |
| Proceeds from the issuance of pre-funded warrants | — | 50,000 |
| Payment of common stock and pre-funded warrant issuance costs | (357) | (641) |
| Proceeds from exercise of employee stock options | 5,723 | 1,061 |
| Proceeds from employee stock purchase plan | 735 | 527 |
| Net cash provided by financing activities | $30,351 | $98,892 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | $(94,280) | $96,436 |
| Cash, cash equivalents and restricted cash—beginning of period | 229,117 | 132,681 |
| Cash, cash equivalents and restricted cash—end of period | $134,837 | $229,117 |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $129,883 | $224,254 |
| Restricted cash | 4,954 | 4,863 |
| Total cash, cash equivalents and restricted cash | $134,837 | $229,117 |
| Supplemental disclosure of noncash items | ||
| Purchases of property and equipment in accounts payable and accrued expenses | $149 | $50 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.